Boehringer Ingelheim and Xencor agreement to develop biobetters

February 22, 2012 3:18 PM

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, and Boehringer Ingelheim announced yesterday a collaboration agreement for certain Xencor biosuperior monoclonal antibodies.

Under the terms of the agreement, Boehringer Ingelheim will provide all manufacturing and product supply from preclinical through Phase I development. Xencor is responsible for preclinical and clinical studies and retains all development and commercial rights to products under the agreement. Upon successful advancement of clinical programs beyond Phase I development, Boehringer Ingelheim has certain manufacturing rights to supply clinical and commercial material to Xencor.

“Xencor has developed a deep portfolio of biosuperior antibodies with the potential for superior clinical and commercial performance, and this collaboration agreement with Boehringer Ingelheim allows us to establish an important relationship with the leading global contract manufacturer of biologics,” said Bassil Dahiyat, Ph.D., president and CEO of Xencor. “Xencor and Boehringer Ingelheim will share the financial risk in early preclinical and clinical development with the incentive of sharing in future success of the programs.”

“We are delighted to start this collaboration with Xencor. It reflects one of our new business models in the contract manufacturing in which both parties are enabled to focus on their core competencies,” stated Corporate Senior Vice President Simon Sturge at Boehringer Ingelheim Biopharmaceuticals.“We are convinced that this creates a win-win situation for both parties.”

Xencor’s lead biosuperior compound is an anti-TNF antibody engineered using the company’s proprietary Xtend™ antibody engineering technology for increasing antibody half-life. Xencor expects to initiate a Phase I trial in 2013 potentially resulting in key human pharmacokinetic data validating Xtend technology.

Editor’s comment: Xencor chose the term “biosuperior” in their press release but in order to stick to the globally accepted terminology, we used “biobetter” while writing this post. From our point of view, “superior” term could be used by the originators who are developing a new version of the current biopharmaceutical. A biosimilar promising to be positively different than the current biopharmaceutical, should be named as “biobetter” as generally accepted.

But in the future, we might add “biosuperior” to our post about biosimilar terminology..

Source: Xencor Press Release

 

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!